WS19.03 Improvements in structural lung disease over 24 months in children with CF aged 6-11 on elexacaftor/tezacaftor/ivacaftor (ETI) – interim analysis using automated LungQ scoringP. McNally, H. Tiddens, J.C. Davies et al.|Journal of Cystic Fibrosis|2025Cited by 0